Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795245 | 1.00 | DHFR (0.69) | DHFR | |
| SCHEMBL4357022 | 0.81 | MAP4K4 (0.54) | DHFR | |
| SCHEMBL9587558 | 0.78 | DHFR (0.72) | DHFR | |
| SCHEMBL14996741 | 0.75 | DHFR (0.67) | DHFR | |
| SCHEMBL4753332 | 0.74 | KMT2A (0.52) | — | |
| SCHEMBL14208448 | 0.74 | DHFR (0.61) | DHFR | |
| SCHEMBL4788363 | 0.74 | DHFR (0.74) | DHFR | |
| SCHEMBL31060856 | 0.74 | DHFR (1.00) | DHFR | |
| SCHEMBL8350468 | 0.74 | DHFR (0.54) | DHFR | |
| SCHEMBL2983014 | 0.73 | PKM (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| CN-1759099-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2006-04-12 | — | — | CN | claimed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| CN-1759099-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2006-04-12 | — | — | CN | disclosed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | CYP3A43, UGT2B7, CYP3A7 | DHFR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.